Abingdon Health Plc

Equities

ABDX

GB00BLF79J41

Medical Equipment, Supplies & Distribution

Delayed London S.E. Other stock markets 06:05:14 2024-05-21 am EDT			5-day change	1st Jan Change
10.78 ^GBX	+0.32%		+10.61%	-1.96%

May. 15	Abingdon pregnancy self-tests now available under the Boots brand	AN
May. 15	Abingdon Health Plans UK Launch of Saliva Pregnancy Test Product for Spring	MT

Abingdon Health Ltd Appoints Chris Yates as CEO

June 30, 2015 at 02:00 am EDT

Imperial Innovations Group plc has led a £3.0 million investment in Abingdon Health Ltd. alongside existing investors. In conjunction with the investment round, Abingdon Health has appointed Chris Yates as CEO. Chris was previously CFO of Immunodiagnostic Systems Holdings PLC and Cozart plc.

Latest news about Abingdon Health Plc

Abingdon pregnancy self-tests now available under the Boots brand	May. 15	AN
Abingdon Health Plans UK Launch of Saliva Pregnancy Test Product for Spring	May. 15	MT
Abingdon Health buys IVDeology Holdings	May. 07	AN
Abingdon Health Plc acquired Ivdeology Holdings Ltd for £0.7 million.	May. 06	CI
Peel Hunt's RetailBook raises GBP2.5 million	Mar. 25	AN
Abingdon Health Completes Design Freeze for STD Self-Tests	Mar. 25	MT
Abingdon Health to Provide Rapid Self-tests to Boots	Mar. 20	MT
Abingdon Health strikes deal amidst upswing in self testing market	Mar. 20	AN
AIM WINNERS & LOSERS: Abingdon Health rises on Boots agreement	Mar. 20	AN
EARNINGS AND TRADING: Smarttech247 and Beeks in deal boosts	Mar. 14	AN
AIM WINNERS & LOSERS: Smartspace backs Sign In bid; Abingdon jumps	Mar. 14	AN
London stocks tread water with US data to come	Mar. 14	AN
ABINGDON HEALTH PLC: BOARD EXPECTS THAT H2 REVENUE WILL BE SIGN…	Mar. 14	RE
Abingdon Health plc Provides Earnings Guidance for the Second Half and Full Fiscal Year 2024	Mar. 14	CI
Abingdon Health Plc Reports Earnings Results for the Half Year Ended December 31, 2023	Mar. 14	CI
Abingdon Health shares down despite decent interim results	Jan. 11	AN
Abingdon Health Plc Announces Promotion of Laura Towse as Group Financial Controller	Jan. 11	CI
Abingdon Health plc Announces Resignation of Andrew Feather as Interim Finance Director	Jan. 11	CI
Abingdon Health Plc Reports Revenue Results for the Six Months Ended December 31, 2023	Jan. 11	CI
Abingdon expects higher half-year revenue	Dec. 15	AN
Stocks edge higher ahead of slew of PMIs	Dec. 15	AN
FTSE 100 Closes Up on Tech Earnings Expectations, Easing Bond Yields	23-10-24	DJ
Abingdon Health appoints Feather as new interim finance director	23-10-24	AN
Abingdon Health Names Interim Finance Director	23-10-24	MT
Abingdon Health Plc Announces Executive Changes	23-10-24	CI

Chart Abingdon Health Plc

Duration

Period

More charts

Company Profile

Abingdon Health plc provides lateral flow contract development and manufacturing (CDMO services) and related contract services to an international customer base. It offers its services to an international customer base across industry sectors, which include clinical, self-testing, animal health, plant health, and environmental testing. Its segments include Product sales, Contract manufacturing, Contract development, and Regulatory. Its regulatory services include technical file build, regulatory filing support, implementation of quality management systems and quality assurance. The Companyâs CDMO division offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Its Abingdon Simply Test range of self-tests is an ecommerce platform that offers a range of self-tests to enable consumers to manage their own health and wellbeing.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-11-13 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
ABINGDON HEALTH PLC	-1.96%	42.74M
BIOMÉRIEUX	-5.96%	12.23B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-3.86%	8.17B
LANTHEUS HOLDINGS, INC.	+33.66%	5.74B
AUTOBIO DIAGNOSTICS CO., LTD.	-7.35%	4.24B
10X GENOMICS, INC.	-55.63%	2.97B
ANDON HEALTH CO., LTD.	+13.62%	2.73B
VITROLIFE AB	-3.75%	2.38B
MYRIAD GENETICS, INC.	+30.67%	2.26B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-4.31%	1.87B

Diagnostic & Testing Substances